Q-Codes
Q2000–Q2999: Temporary Codes
Q2000–Q2999
- Q2004Irrigation solution for treatment of bladder calculi, for example renacidin, per 500 ml
- Q2009Injection, fosphenytoin, 50 mg phenytoin equivalent
- Q2017Injection, teniposide, 50 mg
- Q2026Injection, radiesse, 0.1 ml
- Q2028Injection, sculptra, 0.5 mg
- Q2034Influenza virus vaccine, split virus, for intramuscular use (agriflu)
- Q2035Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria)
- Q2036Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval)
- Q2037Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin)
- Q2038Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone)
- Q2039Influenza virus vaccine, not otherwise specified
- Q2040Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
- Q2041Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2042Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2043Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion
- Q2049Injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mg
- Q2050Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg
- Q2052Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)
- Q2053Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2054Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2055Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2056Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2057Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2058Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion